Conference Coverage

Frontline immunotherapy boosts survival in NSCLC patients

Publish date: June 4, 2018

 

REPORTING FROM ASCO 2018


Merck funded the study. Dr. Lopes disclosed institutional research funding from Merck Sharp & Dohme, EMD Serono, and AstraZeneca. Dr. Heymach disclosed stock/ownership in Bio-Tree and Cardinal Spine, a consulting or advisory role for Abbvie, ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Genentech, Medivation, Novartis, Oncomed, and Synta, and institutional research funding from AstraZeneca. Dr. Gandhi reported having no relevant disclosures.

SOURCE: Lobes G et al. ASCO 2018, abstract LBA4.

Pages

Recommended Reading

Delay of NSCLC surgery can lead to worse prognosis
MDedge Hematology and Oncology
E-cigarette usage has changed
MDedge Hematology and Oncology
Is cancer immunotherapy more effective in men than women?
MDedge Hematology and Oncology
Upfront NGS testing of metastatic NSCLC saves money, time
MDedge Hematology and Oncology
Palliative care may reduce suicide among lung cancer patients
MDedge Hematology and Oncology
Checkpoint inhibitors well tolerated by NSCLC patients with preexisting autoimmune disease
MDedge Hematology and Oncology
Uptake of lung cancer screening is exceedingly low
MDedge Hematology and Oncology
Screening for brain mets could improve quality of life for some with breast cancer
MDedge Hematology and Oncology
A blood test to detect lung cancer inches toward the clinic
MDedge Hematology and Oncology
Atezolizumab has PFS benefit in first-line squamous NSCLC
MDedge Hematology and Oncology